Amgen (AMGN) Competitors $297.60 +2.50 (+0.85%) As of 02:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AMGN vs. GILD, MRNA, VRTX, ABBV, BMY, JNJ, LLY, MRK, PFE, and REGNShould you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Moderna (MRNA), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), Pfizer (PFE), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "medical" sector. Amgen vs. Its Competitors Gilead Sciences Moderna Vertex Pharmaceuticals AbbVie Bristol Myers Squibb Johnson & Johnson Eli Lilly and Company Merck & Co., Inc. Pfizer Regeneron Pharmaceuticals Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends. Do analysts rate GILD or AMGN? Gilead Sciences currently has a consensus price target of $112.36, suggesting a potential downside of 0.95%. Amgen has a consensus price target of $307.27, suggesting a potential upside of 3.25%. Given Amgen's higher possible upside, analysts clearly believe Amgen is more favorable than Gilead Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gilead Sciences 0 Sell rating(s) 8 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.81Amgen 2 Sell rating(s) 12 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.35 Is GILD or AMGN more profitable? Gilead Sciences has a net margin of 20.76% compared to Amgen's net margin of 17.39%. Amgen's return on equity of 176.11% beat Gilead Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Gilead Sciences20.76% 51.93% 17.40% Amgen 17.39%176.11%12.39% Do institutionals & insiders have more ownership in GILD or AMGN? 83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 0.8% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is GILD or AMGN a better dividend stock? Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 2.8%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.2%. Gilead Sciences pays out 66.5% of its earnings in the form of a dividend. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has increased its dividend for 10 consecutive years and Amgen has increased its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Which has preferable valuation & earnings, GILD or AMGN? Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGilead Sciences$28.75B4.91$480M$4.7523.88Amgen$33.42B4.79$4.09B$10.9627.15 Does the media refer more to GILD or AMGN? In the previous week, Gilead Sciences had 25 more articles in the media than Amgen. MarketBeat recorded 70 mentions for Gilead Sciences and 45 mentions for Amgen. Amgen's average media sentiment score of 1.35 beat Gilead Sciences' score of 1.20 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 51 Very Positive mention(s) 2 Positive mention(s) 14 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Amgen 40 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, GILD or AMGN? Gilead Sciences has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. SummaryAmgen beats Gilead Sciences on 11 of the 20 factors compared between the two stocks. Get Amgen News Delivered to You Automatically Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AMGN vs. The Competition Export to ExcelMetricAmgenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$159.88B$2.98B$5.45B$9.29BDividend Yield3.16%2.39%4.71%4.06%P/E Ratio27.1323.3429.4724.30Price / Sales4.79282.80418.80168.61Price / Cash9.9242.2235.8358.21Price / Book27.238.488.275.54Net Income$4.09B-$55.06M$3.24B$259.03M7 Day Performance-2.93%-4.27%-3.77%-4.63%1 Month Performance2.44%12.19%5.61%5.86%1 Year Performance-11.30%3.50%22.78%15.16% Amgen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AMGNAmgen4.5353 of 5 stars$297.60+0.8%$307.27+3.2%-11.2%$159.88B$33.42B27.1328,000Positive NewsUpcoming EarningsGILDGilead Sciences4.8363 of 5 stars$113.07-2.7%$112.36-0.6%+47.6%$140.51B$28.74B23.7817,600Positive NewsUpcoming EarningsInsider TradeMRNAModerna4.4527 of 5 stars$34.11-0.1%$46.11+35.2%-75.2%$13.19B$3.24B-3.915,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeGap DownVRTXVertex Pharmaceuticals4.3018 of 5 stars$464.44-1.1%$512.30+10.3%-7.8%$119.19B$11.02B-118.406,100Positive NewsUpcoming EarningsShort Interest ↑ABBVAbbVie4.5912 of 5 stars$188.71-0.8%$211.29+12.0%+2.0%$333.15B$57.37B80.2655,000Trending NewsEarnings ReportAnalyst ForecastBMYBristol Myers Squibb4.8876 of 5 stars$47.61-1.7%$58.53+22.9%-8.8%$96.86B$48.30B17.8334,100Trending NewsEarnings ReportAnalyst ForecastJNJJohnson & Johnson4.685 of 5 stars$166.12-1.3%$174.50+5.0%+4.4%$399.64B$88.82B17.76138,100Trending NewsAnalyst RevisionLLYEli Lilly and Company4.9204 of 5 stars$807.91-0.6%$1,012.56+25.3%-8.0%$764.91B$45.04B65.6747,000Trending NewsUpcoming EarningsMRKMerck & Co., Inc.4.9963 of 5 stars$84.35-0.4%$108.69+28.9%-30.9%$211.74B$63.92B12.2775,000Positive NewsEarnings ReportAnalyst ForecastOptions VolumeAnalyst RevisionPFEPfizer4.9546 of 5 stars$24.37-1.7%$28.55+17.2%-23.8%$138.47B$63.63B17.6581,000Trending NewsUpcoming EarningsREGNRegeneron Pharmaceuticals4.8209 of 5 stars$562.31-0.1%$828.86+47.4%-49.5%$60.70B$14.20B14.3115,106Trending NewsAnalyst ForecastGap Up Related Companies and Tools Related Companies GILD Competitors MRNA Competitors VRTX Competitors ABBV Competitors BMY Competitors JNJ Competitors LLY Competitors MRK Competitors PFE Competitors REGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AMGN) was last updated on 8/1/2025 by MarketBeat.com Staff From Our PartnersWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!99.8% voted YES on this crypto partnership Kraken—one of the world's biggest crypto exchanges—just picked O...Crypto 101 Media | SponsoredIf you saw this, you'd be scared tooMarkets may look strong—but one veteran analyst warns we’re nearing a financial breaking point. After 40+ y...InvestorPlace | SponsoredWhy “The Prophet” Is Betting Big on This $10 StockAmerica's Biggest Land Grab Is Not Where You Think While the media focuses on coastal cities and farmland.....Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amgen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AMGN Stock Alerts